Co-Development and Acquisition of Domestic Distribution Rights for AKP-009
First written in FY2021-Q2. 2 of 5 entries say "Advanced", first in FY2022-Q2. Latest entry: FY2026-H1.
0 other companies' latest entry also says "Dropped".
- FY2026-H1DroppedAnnual report
「AKP-009 Aska Pharmaceutical Co., Ltd. Japan Upfront payment Development milestones Royalties at a fixed rate Supply price 2020 Until the later of the date two years after the first listing of a generic version of the product on the National Health Insurance drug price list or the date 10 years after the product launch, plus automatic renewal」
The license-in agreement for AKP-009, under which a repeat trial was planned following completion of the additional Phase I trial, was terminated. - FY2023Plans for a repeat trial following completion of the Phase I trialAnnual report
「For AKP-009, a treatment for benign prostatic hyperplasia, the company completed in the first quarter of the fiscal year ending March 2023 the additional Phase I clinical trial initiated by the originator, Aska Pharmaceutical Co., Ltd., in September 2021. Following the evaluation of the results, Aska Pharmaceutical Co., Ltd. plans to conduct another Phase I clinical trial.」
Although AKP-009 completed the additional Phase I clinical trial, the originator plans to conduct another Phase I trial based on the evaluation of the results. - FY2023-Q1AdvancedAnnual report
「For AKP-009, a treatment for benign prostatic hyperplasia, the company completed during the cumulative first-quarter period the additional Phase I clinical trial initiated by the originator, Aska Pharmaceutical Co., Ltd., in September 2021.」
AKP-009 progressed to the completion of the additional high-dose Phase I clinical trial. - FY2022-Q2AdvancedAnnual report
「For AKP-009, a treatment for benign prostatic hyperplasia, the originator, Aska Pharmaceutical Co., Ltd., determined that a further study at a higher dose was necessary to confirm the product's maximum efficacy based on the results of the Phase II clinical trial in the previous fiscal year, and began an additional Phase I clinical trial in September 2021.」
For AKP-009, an additional high-dose Phase I clinical trial was initiated in September 2021 to confirm maximum efficacy following the Phase II trial. - FY2021-Q2First statedAnnual report
「In September of that year, we entered into an agreement with ASKA Pharmaceutical Co., Ltd. covering the co-development and sale of AKP-009, a treatment for benign prostatic hyperplasia, and acquired co-development and marketing rights for the product in Japan.」
Under the agreement with ASKA Pharmaceutical, the Group acquired co-development and marketing rights for AKP-009 in Japan.